Summary of Key Points
Seven years since the launch of the STAR Market, it has become a leading platform for high-tech companies, with over 600 enterprises and a market value of 15 trillion yuan. It not only provides capital for the rapid growth of high-tech firms but also offers clear exit routes for venture capital (VC) institutions, transforming the strategy of "investing early, in small companies, and in high-tech" from a risky endeavor into a viable choice supported by policies, the market, and industry trends. As a representative of early-stage investors, Fuhui Venture Capital has achieved significant success with its founder's entrepreneurial experience, deep collaboration with the Chinese Academy of Sciences (CAS), and favorable policy frameworks. They have invested in notable companies such as Cambricon, Changguang Huaxin, and Zhongke Fuhai, and plan to focus on sectors like biomedicine and semiconductors in the future.
The STAR Market: A Platform for Mutual Empowerment between High-Tech and VC Institutions
The greatest contribution of the STAR Market over the past seven years has been solving two critical issues:
1. Financing for high-tech companies: Many technically strong startups lacking funding previously struggled to obtain capital. The STAR Market has lowered the barriers to listing, allowing over 600 companies to raise funds and expand their production and research and development (R&D) efforts.
2. Encouraging VC investment in early stages: VC institutions rely on company listings or acquisitions for returns. Before the STAR Market, exit options were limited and slow, leading them to prefer investing in mature companies preparing for IPOs. Now, with clear exit pathways, they are more willing to invest in startups still in the R&D phase, confident that they can eventually list on the STAR Market.
In short, the STAR Market acts as a bridge, connecting high-tech startups with capital providers, creating opportunities for both parties.
Why Fuhui Venture Capital Invests Early and in Small Companies
The founder of Fuhui Venture Capital, Zeng Jun, explains their approach:
- Personal experience: In the 1990s, Zeng invested 50,000 yuan in a technology from a CAS doctor and founded the fire safety company Gulf Holdings, which later went public in Hong Kong and was acquired by a Fortune 500 company. This experience taught him that early-stage technologies have great potential but often go unnoticed by financial investors due to high risks.
- Policy support: In 2008, when Fuhui Venture Capital was established, the government introduced policies to encourage investment in early-stage companies. They became one of the first VC firms in the emerging industries to receive official support, giving them the confidence to continue this approach.
Technology Commercialization Requires More Than Just Funding
While the CAS is a rich source of technological innovations, funding alone is not enough to turn lab ideas into profitable products. Fuhui Venture Capital takes a comprehensive approach:
- Full-chain support: For example, in collaboration with the CAS Institute of Physics and Chemistry, they provide funding, build production lines, find sales channels, and mediate conflicts between scientists and entrepreneurs.
- Fund structure for scalability: They manage a parent-fund model, setting up subsidiary funds to partner with multiple research institutes. This not only provides capital but also builds equity investment platforms, enabling the institutes to share in company growth and motivating researchers to commercialize their innovations.
Investment Success Stories
Fuhui Venture Capital's portfolio includes several notable companies:
- Cambricon: Invested in the B round in 2019; listed on the STAR Market the following year as China's first AI chip company.
- Changguang Huaxin: Invested in the B round in 2018 and listed on the STAR Market in 2022 with a market value of over 70 billion yuan.
- Zhongke Fuhai: Established in 2016, began listing preparations in 2025, and completed a 1-billion yuan Pre-IPO in 2026 with a valuation of 9 billion yuan, setting a benchmark for the ultra-low temperature technology sector.
These cases demonstrate that early-stage investments can lead to significant success if the technology is solid and supported properly.
Future Focus: Biomedicine and Semiconductors
Fuhui Venture Capital's future directions are clear:
- Biomedicine: Collaborating with the CAS Shanghai Institute of Materia Medica, they have established an early-stage biopharmaceutical fund in Zhongshan, Guangdong, investing in over 20 projects. Some have licensed their technology to overseas companies, while others are preparing for IPOs in the Hong Kong stock market.
- Semiconductors and new energy: They will continue to focus on these high-tech sectors, which are key drivers of national development and offer exit opportunities through the STAR Market.
In summary, the STAR Market has facilitated a mutually beneficial relationship between high-tech companies and VC institutions. Fuhui Venture Capital's success shows that with the right approach, patience, and support, early-stage investments can yield substantial returns and help countries overcome technological challenges.